Coexpression by vaccinia virus recombinants of equine herpesvirus 1 glycoproteins gp13 and gp14 results in potentiated immunity

The equine herpesvirus 1 glycoprotein 14 (EHV-1 gp14) gene was cloned, sequenced, and expressed by vaccinia virus recombinants. Recombinant virus vP613 elicited the production of EHV-1-neutralizing antibodies in guinea pigs and was effective in protecting hamsters from subsequent lethal EHV-1 challe...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Virology 1990-05, Vol.64 (5), p.2399-2406
Main Authors: Guo, P. (Purdue University, West Lafayette, IN), Goebel, S, Perkus, M.E, Talor, J, Norton, E, Allen, G, Languet, B, Desmettre, P, Paoletti, E
Format: Article
Language:English
Subjects:
Amino Acid Sequence
Animals
Antibodies, Viral - analysis
Antibody Formation
Base Sequence
CABALLOS
CHEVAL
Cloning, Molecular - methods
Cricetinae
Gene Expression
Genes, Viral
GLICOPROTEINAS
GLYCOPROTEINE
Guinea Pigs
Herpesviridae - genetics
Herpesviridae Infections - immunology
Herpesviridae Infections - prevention & control
Herpesvirus 1, Equid - genetics
Herpesvirus 1, Equid - immunology
HERPETOVIRIDAE
Membrane Glycoproteins - genetics
Membrane Glycoproteins - immunology
Molecular Sequence Data
Neutralization Tests
Oligonucleotide Probes
ORTHOPOXVIRUS
RECOMBINACION
RECOMBINAISON
REPONSE IMMUNITAIRE
RESPUESTA INMUNOLOGICA
Vaccinia virus - genetics
Viral Envelope Proteins - genetics
Viral Envelope Proteins - immunology
Viral Structural Proteins - genetics
Viral Vaccines - administration & dosage
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The equine herpesvirus 1 glycoprotein 14 (EHV-1 gp14) gene was cloned, sequenced, and expressed by vaccinia virus recombinants. Recombinant virus vP613 elicited the production of EHV-1-neutralizing antibodies in guinea pigs and was effective in protecting hamsters from subsequent lethal EHV-1 challenge. Coexpression of EHV-1 gp14 in vaccinia virus recombinant vP634 along with EHV-1 gp13 (P. Guo, S. Goebel, S. Davis, M. E. Perkus, B. Languet, P. Desmettre, G. Allen, and E. Paoletti, J. Virol. 63:4189-4198, 1989) greatly enhanced the protective efficacy in the hamster challenge model over that obtained with single recombinants. The inoculum doses (log10) required for protection of 50% of hamsters were 6.1 (EHV-1 gp13), 5.2 (EHV-1 gp14), and 3.6 (vaccinia virus recombinant expressing both EHV-1 glycoproteins [gp13 and gp14])
ISSN:0022-538X
1098-5514
DOI:10.1128/JVI.64.5.2399-2406.1990